Abstract
Background: Aging is associated with increased lipid peroxidation (LP). D-003, a mixture of long-chain aliphatic primary acids purified from sugar cane wax, has been found to inhibit LP in experimental models and in healthy subjects.
Objectives: The aim of this study was to assess the effects of D-003 on LP markers and the lipid profile of older individuals.
Methods: This randomized, double-blind, placebo-controlled study was conducted at the Plaza Veterans' House, Havana City, Cuba. Male and female patients aged ≥60 years with total cholesterol values of <6.1 mmol/L were eligible for inclusion in the study. After a 3-week lead-in and baseline assessment period, patients were randomized to receive PO D-003 5 mg/d, D-003 10 mg/d, or placebo for 8 weeks. The effect on copper-induced LP of low-density lipoprotein (LDL) particles was the primary variable, and the effects on plasma total antioxidant status (TAS), plasma malondialdehyde (MDA) concentration, plasma antioxidant enzyme (superoxide dismutase and glutathione peroxidase) activities, and the lipid profile were secondary variables. A clinical examination was performed at each visit (baseline, weeks 4 and 8). A clinical examination, LP, and blood tests (lipid profile, hematologic, and blood biochemistry safety indicators) were performed at baseline and after 8 weeks of treatment. Compliance and adverse events (AEs) were assessed at weeks 4 and 8. A 2-tailed P < 0.05 was considered statistically significant for comparisons of both continuous and categoric variables.
Results: Fifty-four patients aged ≥60 years were assessed for inclusion in the study, and 51 patients (40 women, 11 men; mean [SD] age, 67 [6] years) were included in the study. The lag phase of conjugated diene formation increased significantly and in a dose-dependent manner in the group treated with D-003 5 mg (24.7%; P < 0.01) and in the group treated with D-003 10 mg (29.3%; P < 0.01) compared with placebo. The maximal rate of conjugated diene propagation decreased significantly in the D-003 5- and 10-mg groups −22.7% and −25.8%, respectively; both, P < 0.05) compared with placebo. TAS increased significantly (17.7% and 23.0%, respectively; both, P < 0.01) in both active treatment groups compared with placebo. Plasma MDA concentration decreased significantly in the D-003 10-mg group (−28.6%; P < 0.05) but not in the D-003 5-mg group, compared with placebo. These changes were also significant compared with baseline. Antioxidant enzyme activities did not change in the active treatment groups compared with placebo or baseline. In the D-003 5- and 10-mg groups, significant decreases were found in LDL cholesterol concentration (−15.8% and −23.8%, respectively; both, P < 0.001) and total cholesterol concentration (−13.0% and −16.8%, both, P < 0.05) compared with placebo. High-density lipoprotein cholesterol concentration increased significantly in the D-003 5-mg group (5.7%; P < 0.05) and the D-003 10-mg group (18.2%; P < 0.001) compared with placebo. Changes in the lipid profile were also significant compared with baseline. In the placebo group, no variable changed significantly compared with baseline. D-003 was well tolerated at both dose levels, and no patient withdrew from the study. There were a total of 3 AEs reported: insomnia and acidity in 2 patients receiving placebo; and heartburn in 1 patient receiving D-003 5 mg.
Conclusions: D-003 5 and 10 mg/d administered to these older individuals (aged ≥60 years) for 8 weeks inhibited LP of LDL and increased TAS in a dose-dependent manner, while plasma MDA concentration decreased in the patients receiving D-003 10 mg/d only. D-003 was well tolerated at both doses
Key Words: D-003, lipid peroxidation, antioxidant compounds, lipid-lowering, elderly, sugar cane wax acids
Full Text
The Full Text of this article is available as a PDF (759.6 KB).
References
- 1.World Health Organization Fact sheet No. 317. Cardiovascular diseases. October 25, 2007. http://www.who.int/mediacentre/factsheets/fs317/en/index.html Accessed.
- 2.Murray CJ, Lopez AD. Alternate projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet. 1997;349:1498–1504. doi: 10.1016/S0140-6736(96)07492-2. [DOI] [PubMed] [Google Scholar]
- 3.The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterd lowering. JAMA. 1984;251:365–374. [PubMed] [Google Scholar]
- 4.Frick MH, Elo O, Happa K. Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987;317:1237–1245. doi: 10.1056/NEJM198711123172001. [DOI] [PubMed] [Google Scholar]
- 5.Randomised trial of chdesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S) Lancet. 1994;344:1383–1389. [PubMed] [Google Scholar]
- 6.The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Ned. 1998;339:1349–1357. doi: 10.1056/NEJM199811053391902. [DOI] [PubMed] [Google Scholar]
- 7.Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet. 2002;360:7–22. [Google Scholar]
- 8.Shepherd J, Blauw GJ, Murphy MB, PROSPER Study Group (PROspective Study of Pravastatin in the Elderly at Risk Pravastatin in elderly individuals at risk of vascular disease. A randomised controlled trial. Lancet. 2002;360:1623–1630. doi: 10.1016/s0140-6736(02)11600-x. [DOI] [PubMed] [Google Scholar]
- 9.Krumholz HM, Seeman TE, Merrill SS. Lack of association between cholesterd and coronary heart disease mortality and morbidity and all-cause mortality in persons older than 70 years. JAMA. 1994;272:1335–1340. [PubMed] [Google Scholar]
- 10.Manolio TA, Pearson TA, Wenger NK. Cholesterol and heart disease in older persons and women. Review of an NHLBI workshop. Ann Epidemiol. 1992;2:161–176. doi: 10.1016/1047-2797(92)90051-q. [DOI] [PubMed] [Google Scholar]
- 11.Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterd in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterd in Adults (Adult Treatment Panel III) JAMA. 2001;285:2486–2497. doi: 10.1001/jama.285.19.2486. [DOI] [PubMed] [Google Scholar]
- 12.Luscher TF, Barton M. Biology of the endothelium. Clin Cardiol. 1997;20(Suppl 2):II–3-II-10. [PubMed] [Google Scholar]
- 13.Mas R. D-003: A new substance with promising lipid modifying and pleiotropic effects for atherosclerosis management. Drugs Future. 2004;29:773–786. [Google Scholar]
- 14.Menendez R, Mas R, Amor AM. Inhibition of rat lipoprotein lipid peroxidation by the oral administration of D003, a mixture of very long-chain saturated fatty acids. Can J Physiol Pharmacol. 2002;80:13–21. doi: 10.1139/y01-088. [DOI] [PubMed] [Google Scholar]
- 15.Gamez R, Mendoza S, Mas R. Dose-dependent cholesterol-lowering effects of D-003 on normocholesterolemic rabbits. Curr Ther Res Clin Exp. 2000;61:460–468. [Google Scholar]
- 16.Gamez R, Mendoza S, Mas R. Comparison of the chdesterol-lowering effects and toxicity of D-003 and lovastatin on normocholesterolaemic rabbits. Drugs R D. 2003;4:219–229. doi: 10.2165/00126839-200304040-00002. [DOI] [PubMed] [Google Scholar]
- 17.Mendoza S, Gamez R, Mas R, Goicochea E. Effects of D-003, a mixture of long-chain aliphatic primary acids, fluvastatin and the combined therapy of D-003 plus fluvastatin on the lipid profile of normocholesterolemic rabbits. Int J Tissue React. 2003;25:81–89. [PubMed] [Google Scholar]
- 18.Castaño G, Menéndez R, Más R. Effects of D 003, a new hypocholesterolaemic and antiplatelet compound, on lipid profile and lipid peroxidation in healthy voluteers. Clin Drug Investig. 2003;23:193–203. doi: 10.2165/00044011-200323030-00005. [DOI] [PubMed] [Google Scholar]
- 19.Castaño G, Mas R, Fernandez L. Assessment of the effects of D-003, a new antiplatelet and hypocholesterolemic compound, in healthy volunteers: A phase I clinical study. Drugs R D. 2002;3:337–348. doi: 10.2165/00126839-200203050-00008. [DOI] [PubMed] [Google Scholar]
- 20.Castaño G, Mas R, Fernandez L. Effects of D-003 on the lipid profile of patients with type II hypercholesterolaemia: A phase II clinical study. Clin Drug Investig. 2003;23:789–802. doi: 10.2165/00044011-200323120-00004. [DOI] [PubMed] [Google Scholar]
- 21.Menendez R, Mas R, Amor AM. Inhibition of cholesterol biosynthesis in cultured fibroblasts by D003, a mixture of very long chain saturated fatty acids. Pharmacol Res. 2001;44:299–304. doi: 10.1006/phrs.2001.0851. [DOI] [PubMed] [Google Scholar]
- 22.Menendez R, Mas R, Perez J. Oral administration of D-003, a mixture of very long chain fatty acids, prevents casein-induced endogenous hypercholesterolemia in rabbits. Can J Physiol Pharmacol. 2004;82:22–29. doi: 10.1139/y03-123. [DOI] [PubMed] [Google Scholar]
- 23.Goicochea E. Acute and oral subchronic toxicity of D-003 in rats. Toxicol Lett. 2000;118:31–41. doi: 10.1016/s0378-4274(00)00260-5. [DOI] [PubMed] [Google Scholar]
- 24.Gamez R, Mas R, Noa M. Six-month toxicity study of oral administration of D-003 in Sprague Dawley rats. Drugs R D. 2002;3:375–386. doi: 10.2165/00126839-200203060-00002. [DOI] [PubMed] [Google Scholar]
- 25.Gamez R, Mas R, Noa M. Effects of chronic administration of D-003, a mixture of sugar cane wax high molecular weight acids, in beagle dogs. Drugs Exp Clin Res. 2004;30:75–88. [PubMed] [Google Scholar]
- 26.Gamez R, Gonzalez JE, Rodeiro I. In vivo genotoxic evaluation of D-003, a mixture of very long chain aliphatic acids. J Med Food. 2001;4:85–91. doi: 10.1089/109662001300341743. [DOI] [PubMed] [Google Scholar]
- 27.Rodriguez MD, Gamez R, Gonzalez JE. Lack of developmental toxicity of D-003: A mixture of long-chain fatty acids in rats. Food Chem Toxicol. 2003;41:89–93. doi: 10.1016/s0278-6915(02)00217-x. [DOI] [PubMed] [Google Scholar]
- 28.Schectman G, Hiatt J. Drug therapy for hypercholesterolemia in patients with cardiovascular disease: Factors limiting achievement of lipid goals. Am J Med. 1996;100:197–204. doi: 10.1016/s0002-9343(97)89459-4. [DOI] [PubMed] [Google Scholar]
- 29.Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem. 1979;95:351–358. doi: 10.1016/0003-2697(79)90738-3. [DOI] [PubMed] [Google Scholar]
- 30.Kleinveld HA, Hak-Lemmers HL, Stalenhoef AF, Demacker PN. Improved measurement of low-density-lipoprotein susceptibility to copper-induced oxidation: Application of a short procedure for isolating low-density lipoprotein. Clin Chem. 1992;38:2066–2072. [PubMed] [Google Scholar]
- 31.Esterbauer H, Striegl H, Puhl H, Rotheneder M. Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free Radic Res Commun. 1989;6:67–75. doi: 10.3109/10715768909073429. [DOI] [PubMed] [Google Scholar]
- 32.Menendez R, Mas R, Amor AM. Effects of policosanol treatment on the susceptibility of low density lipoprotein (LDL) isolated from healthy volunteers to oxidative modification in vitro. Br J Clin Pharmacol. 2000;50:255–262. doi: 10.1046/j.1365-2125.2000.00250.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Markwell MA, Hass SM, Bieber LL. A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal Biochem. 1987;87:206–210. doi: 10.1016/0003-2697(78)90586-9. [DOI] [PubMed] [Google Scholar]
- 34.Seigler L, Wu WT. Separation of serum high-density lipoprotein for cholesterol determination: Ultracentrifugation vs precipitation with sodium phosphotungstate and magnesium chloride. Clin Chem. 1981;27:838–841. [PubMed] [Google Scholar]
- 35.Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502. [PubMed] [Google Scholar]
- 36.Ahotupa M, Marniemi J, Lehtimaki T. Baseline diene conjugation in LDL lipids as a direct measure of in vivo LDL oxidation. Clin Biochem. 1998;31:257–261. doi: 10.1016/s0009-9120(98)00018-6. [DOI] [PubMed] [Google Scholar]
- 37.Meraji S, Abuja PM, Hayn M. Relationship between classic risk factors, plasma antioxidants and indicators of oxidant stress in angina pectoris (AP) in Tehran. Atherosclerosis. 2000;150:403–412. doi: 10.1016/s0021-9150(99)00394-9. [DOI] [PubMed] [Google Scholar]
- 38.Khalil A, Fortin JP, LeHoux JG, Fulop T. Age-related decrease of dehydroepiandrosterone concentrations in low density lipoproteins and its role in the susceptibility of low density lipoproteins to lipid peroxidation. J Lipid Res. 2000;41:1552–1561. [PubMed] [Google Scholar]
- 39.Janero DR. Malondialdehyde and thiobarbituric acid-reactivity as diagnostic indices of lipid peroxidation and peroxidative tissue injury. Free Radic Biol Med. 1990;9:515–540. doi: 10.1016/0891-5849(90)90131-2. [DOI] [PubMed] [Google Scholar]
- 40.Young IS, McEneny J. Lipoprotein oxidation and atherosclerosis. Biol Soc Trans. 2001;29:358–362. doi: 10.1042/0300-5127:0290358. [DOI] [PubMed] [Google Scholar]
- 41.Fielding CJ, Fielding PE. Molecular physiology of reverse cholesterd transport. J Lipid Res. 1995;36:211–228. [PubMed] [Google Scholar]
- 42.Meyers CD, Kashyap ML. Pharmacological elevation of high-density lipoprotein: Recent insights on mechanisms of action and atherosclerosis protection. Curr Opin Cardiol. 2004;19:366–373. doi: 10.1097/01.hco.0000126582.27767.87. [DOI] [PubMed] [Google Scholar]